Taseko Announces PDMR Share Transaction
January 14, 2026, Vancouver, BC - Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) ("Taseko" or the "Company") announces that one of its Directors, Rita Maguire, has advised the Company that she exercised a total of 39,000 share options, which are due to expire February 1, 2026.
Executives Share Dealings - Further information
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulations, provides further detail in respect of the transactions as described at the beginning of this announcement.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a. |
Name |
Rita Maguire |
||||
|
2 |
Reason for the notification |
|||||
|
a |
Position/status |
Director |
||||
|
b |
Initial notification/Amendment Initial Notification |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
|
Name |
Taseko Mines Limited |
||||
|
|
Legal Entity Identifier code |
549300XKUO1JSLU7KX54 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a. |
Description of the 2p Ordinary Shares Financial instrument, type of instrument Identification code |
Ordinary Shares
BBG000BTFLR1 |
||||
|
b. |
Nature of the transaction Acquisition of Shares |
1) Exercise of options
|
||||
|
c. |
Price(s) and volume(s) |
|
||||
|
d. |
Aggregated information • Aggregated volume • Price
|
· 39,000 · $1.58 CAD
|
||||
|
e. |
Date of the transaction |
January 12, 2026 |
||||
|
f. |
Place of the transaction |
Toronto Stock Exchange and/or NYSE American |
||||
For further information on Taseko, please visit the Taseko website at www.tasekomines.com or contact:
Brian Bergot, Vice President, Investor Relations - 778-373-4533 or toll free 1-877-441-4533
Stuart McDonald
President and CEO